 | • レポートコード：MRC2302A053P • 出版社/出版日：360iResearch / 2023年2月1日 • レポート形態：英語、PDF、249ページ • 納品方法：Eメール（受注後3日） • 産業分類：実験機器 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社発行の当調査レポートでは、2021年に256.81百万ドルであった世界のmiRNAシーケンシング＆アッセイ市場規模が、2022年に292.43百万ドルに達し、2027年には565.08百万ドルまで年平均14.04％で成長すると予測しています。当レポートは、miRNAシーケンシング＆アッセイの世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別（ライブラリー調製用キット、シーケンシング用消耗品）分析、技術別（イオン半導体シーケンス、ナノポアシーケンス、オリゴヌクレオチドライゲーション＆検出シーケンシング、合成別配列決定）分析、エンドユーザー別（受託研究機関、研究機関＆学術機関）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況など、以下の構成でまとめております。なお、当書には、Abcam PLC、Bio-Rad Laboratories Inc.、F. Hoffmann-La Roche Ltd、Gel Company, Inc.、Global Life Sciences Solutions USA LLC、HTG Molecular Diagnostics, Inc.、Illumina, Inc.、Integrated DNA Technologies, Inc.、Kaneka Corporation、Lexogen GmbH、Meridian Bioscience, Inc、New England Biolabs, Inc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のmiRNAシーケンシング＆アッセイ市場規模：製品別 - ライブラリー調製用キットの市場規模 - シーケンシング用消耗品の市場規模 ・世界のmiRNAシーケンシング＆アッセイ市場規模：技術別 - イオン半導体シーケンスの市場規模 - ナノポアシーケンスの市場規模 - オリゴヌクレオチドライゲーション＆検出シーケンシングの市場規模 - 合成別配列決定の市場規模 ・世界のmiRNAシーケンシング＆アッセイ市場規模：エンドユーザー別 - 受託研究機関における市場規模 - 研究機関＆学術機関における市場規模 ・世界のmiRNAシーケンシング＆アッセイ市場規模：地域別 - 南北アメリカのmiRNAシーケンシング＆アッセイ市場規模 アメリカのmiRNAシーケンシング＆アッセイ市場規模 カナダのmiRNAシーケンシング＆アッセイ市場規模 ブラジルのmiRNAシーケンシング＆アッセイ市場規模 ... - アジア太平洋のmiRNAシーケンシング＆アッセイ市場規模 日本のmiRNAシーケンシング＆アッセイ市場規模 中国のmiRNAシーケンシング＆アッセイ市場規模 インドのmiRNAシーケンシング＆アッセイ市場規模 韓国のmiRNAシーケンシング＆アッセイ市場規模 台湾のmiRNAシーケンシング＆アッセイ市場規模 ... - ヨーロッパ/中東/アフリカのmiRNAシーケンシング＆アッセイ市場規模 イギリスのmiRNAシーケンシング＆アッセイ市場規模 ドイツのmiRNAシーケンシング＆アッセイ市場規模 インドのmiRNAシーケンシング＆アッセイ市場規模 フランスのmiRNAシーケンシング＆アッセイ市場規模 ロシアのmiRNAシーケンシング＆アッセイ市場規模 ... - その他地域のmiRNAシーケンシング＆アッセイ市場規模 ・競争状況 ・企業情報 |
The Global miRNA Sequencing & Assay Market size was estimated at USD 256.81 million in 2021 and expected to reach USD 292.43 million in 2022, and is projected to grow at a CAGR 14.04% to reach USD 565.08 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the miRNA Sequencing & Assay to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Library Preparation Kits and Sequencing Consumables.
Based on Technology, the market was studied across Ion Semiconductor Sequencing, Nanopore Sequencing, Sequencing By Oligonucleotide Ligation and Detection, and Sequencing By Synthesis.
Based on End User, the market was studied across Contract Research Organizations and Research and Academic Institutes.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for miRNA Sequencing & Assay market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the miRNA Sequencing & Assay Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global miRNA Sequencing & Assay Market, including Abcam PLC, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd, Gel Company, Inc., Global Life Sciences Solutions USA LLC, HTG Molecular Diagnostics, Inc., Illumina, Inc., Integrated DNA Technologies, Inc., Kaneka Corporation, Lexogen GmbH, Meridian Bioscience, Inc, New England Biolabs, Inc., Norgen Biotek Corporation, Oxford Nanopore Technologies Limited, Pacific Biosciences of California, Inc, Perkinelmer, Inc., Rosetta Genomics Ltd., Sigma Aldrich Corp., System Biosciences LLC, Takara Bio, Inc., Thermo Fisher Scientific Inc, and TriLink BioTechnologies, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global miRNA Sequencing & Assay Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global miRNA Sequencing & Assay Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global miRNA Sequencing & Assay Market?
4. What is the competitive strategic window for opportunities in the Global miRNA Sequencing & Assay Market?
5. What are the technology trends and regulatory frameworks in the Global miRNA Sequencing & Assay Market?
6. What is the market share of the leading vendors in the Global miRNA Sequencing & Assay Market?
7. What modes and strategic moves are considered suitable for entering the Global miRNA Sequencing & Assay Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Introduction of various techniques to assess the miRNA sequence
5.1.1.2. Increased prevalence of infectious diseases
5.1.1.3. Surge in the number of cancer incidences
5.1.2. Restraints
5.1.2.1. Lack of skilled professionals
5.1.3. Opportunities
5.1.3.1. Growing popularity for cost effective sequencing techniques
5.1.3.2. Increase in the number of research in genetic segment
5.1.4. Challenges
5.1.4.1. High initial investment on infrastructure
5.2. Cumulative Impact of COVID-19
6. miRNA Sequencing & Assay Market, by Product
6.1. Introduction
6.2. Library Preparation Kits
6.3. Sequencing Consumables
7. miRNA Sequencing & Assay Market, by Technology
7.1. Introduction
7.2. Ion Semiconductor Sequencing
7.3. Nanopore Sequencing
7.4. Sequencing By Oligonucleotide Ligation and Detection
7.5. Sequencing By Synthesis
8. miRNA Sequencing & Assay Market, by End User
8.1. Introduction
8.2. Contract Research Organizations
8.3. Research and Academic Institutes
9. Americas miRNA Sequencing & Assay Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific miRNA Sequencing & Assay Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa miRNA Sequencing & Assay Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Abcam PLC
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Bio-Rad Laboratories Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. F. Hoffmann-La Roche Ltd
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Gel Company, Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Global Life Sciences Solutions USA LLC
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. HTG Molecular Diagnostics, Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Illumina, Inc.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Integrated DNA Technologies, Inc.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Kaneka Corporation
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Lexogen GmbH
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Meridian Bioscience, Inc
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. New England Biolabs, Inc.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Norgen Biotek Corporation
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Oxford Nanopore Technologies Limited
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Pacific Biosciences of California, Inc
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Perkinelmer, Inc.
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Rosetta Genomics Ltd.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Sigma Aldrich Corp.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. System Biosciences LLC
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. Takara Bio, Inc.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Thermo Fisher Scientific Inc
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. TriLink BioTechnologies, Inc.
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing